)
)
Seagen Investor Relations Material
Latest events
Q4 2022
Seagen
Access the full event backlog
Slides, Transcripts, and Reports from 12,000+ public companies
Latest reports from Seagen Inc
Access all reports
Segment Data
Access more data
Revenue by
Source
Net product sales
Royalty revenues
Collaboration and license agreement revenues
Expenses by
Financials
Seagen Inc., a biotechnology company, develops and commercializes therapies for the treatment of cancer. The company markets LONZA (vinorelbine tartrate) injection, which is used to treat various types of cancer. It also focuses on the development of Seaglass (poly-L-glutamic acid), a compound that is undergoing clinical study for the treatment of chemotherapy-induced nausea and vomiting (CINV). The company was formerly known as Ocean Pharmaceuticals, Inc. and changed its name to Seagen Inc. in August 1995. Seagen Inc. is based in Bothell, Washington.
Latest articles
)
Axon: Making Bullets Obsolete
Axon transformed the TASER from a struggling invention into a $50B public safety giant, redefining policing with tech-driven solutions.
21 Feb 2025
)
Robert G. Hagstrom: Darwinian Investing and Multidisciplinary Wisdom
Robert G. Hagstrom, author of The Warren Buffett Way, explores how interdisciplinary thinking shapes his investing, from Adler's reading to Darwinian markets.
7 Feb 2025
)
Quartr Brings Stories Behind the Numbers to Light
Quartr simplifies access to IR material and puts qualitative insights and company narratives front and center.
3 Feb 2025
Ticker symbol
SGEN
Country
🇺🇸 United States